Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis

Ioan Sporea, Alina Popescu, Roxana Şirli, Ovidiu Golea, Camelia Totolici, Mirela Dănilă, Corina Vernic

AIM: To evaluate the response to pegylated-interferon alpha 2a in chronic hepatitis C patients on chronic haemodialysis.

METHODS: Ten patients with chronic C hepatitis were enrolled in this study. All had increased aminotransferases for more than 6 mo, positive antiHCV antibodies and positive PCR HCV-RNA. We administrated Peg-Interferon alpha 2a 180 µg/wk for 48 wk. After 12 wk of treatment we evaluated the biochemical and early virological response (EVR). At the end of the treatment we evaluated the biochemical response and 24 wk after the end of the treatment we evaluated the sustained virological response (SVR). We monitored the side-effects during the treatment.

RESULTS: Two patients dropped out in the first 12 wk of treatment and 2 after the first 12 wk of treatment. After 12 wk of treatment, 7 out of 8 patients had biochemical response and EVR and 1 had biochemical response but persistent viremia. We had to reduce the dose of pegylated-interferon to 135 µg/wk in 2 cases. Three out of 6 (50%) patients had SVR 24 wk after the end of the treatment. Intention-to-treat analysis showed that 3 out of 10 patients (30%) had SVR. Side-effects occurred in most of the patients (flu-like syndrome, thrombocytopenia or leucopenia), but they did not impose the discontinuation of treatment.

CONCLUSION: After 12 wk of treatment with Peg-Interferon alpha 2a (40 ku) in patients on chronic haemodialysis with chronic C hepatitis, EVR was obtained in 87.5% (7/8) of the cases. SVR was achieved in 50% of the cases (3/6 patients) that finished the 48 wk of treatment.

INTRODUCTION

Although constant efforts have been made to improve the outcome of hepatitis C patients, chronic infection with hepatitis C virus (HCV) remains a problem for hepatologists. The development of new therapeutic formulas (pegylation) and the introduction of ribavirin were major steps forward. However, the problem is not entirely solved since the sustained virological response can be obtained in only half of HCV-infected patients. There are also the special groups of patients (with liver cirrhosis, with HIV coinfection, patients on chronic haemodialysis) in which the optimal antiviral treatment is still not established.

In patients on chronic haemodialysis, the number of individuals infected with HCV is rather high mostly due to nosocomial infection. The reported prevalence of HCV infection ranges from 8% to 20% in dialysis patients in developed countries and much higher in less developed countries. The prevalence of anti-HCV among dialysis patients was 43.9% in Saudi Arabia in 2001, 30% in India in 2002, and 41% in Turkey (2001). In United States of America in 2000, 8.4% of haemodialysis patients were anti-HCV positive. The incidence of HCV infection is higher in patients undergoing dialysis at hospitals than in those undergoing haemodialysis or peritoneal dialysis at home.

The main mechanisms involved in nosocomial infection with HCV in haemodialysis patients are filter reuse, use of contaminated haemodialysis machines and contamination of medical staff’s hands. It has been proven that the incidence of HCV infection in haemodialysis patients increases if the nurse does not change her gloves before injecting each patient and if HCV (+) patients undergo haemodialysis in the same room with HCV (-) patients.
Other possible risk factors for transmission of the virus are sharing single vials to prepare drugs or infusions for different patients, distance less then one meter between chairs\cite{13}, sharing a single heparin-saline solution ampoule in different patients\cite{14}. A large French multi-center study\cite{15} on 1323 haemodialyzed patients has shown an incidence of 0.4% new HCV infections per year, almost two thirds of them occurring in infected patients on dialysis during the same shift at the same unit.

Regardless of the route of infection, the evolution of HCV-infected patients on chronic haemodialysis is often severe. Martin et al\cite{16} showed that 24% of haemodialysis patients with positive anti-HCV Ab have liver cirrhosis and that there is no correlation between the severity of hepatic lesions and viral genotype, viral load or transaminase level. Hence we must treat chronic hepatitis C in haemodialysis patients, particularly in those on the waiting list for renal transplantation, because post-transplant immunosuppressive therapy can accelerate the natural course of the liver disease. Interferon-based therapy is not recommended in HCV positive patients after renal transplantation due to a significant risk of graft loss and a low rate of clearance of the virus\cite{17,18}. Also ribavirin monotherapy for renal transplant recipients positive for anti-HCV is associated with improvement in liver enzymes but not significant change of HCV RNA\cite{19}. On the other hand, Kamar et al\cite{20} showed that treatment of HCV positive haemodialysis patients with interferon α could induce complete and sustained clearance of the virus in almost 29% of them, without any relapses after renal transplantation despite subsequent immunosuppressive treatment.

Another problem of the treatment for HCV-infected patients on dialysis is the contraindication of ribavirin, due to the risk of deep and long-lasting haemolytic anaemia\cite{21}.

Due to these characteristics of this special group of patients and the promising results of our previous study using standard interferon in haemodialysis patients\cite{22}, we decided to evaluate the effect of pegylated-interferon in patients with chronic hepatitis C on dialysis.

**MATERIALS AND METHODS**

We included 10 haemodialysis patients in our study (4 males and 6 females, mean age 40.2 years). Written informed consent to participate in this study was obtained from all of them. All had increased aminotransferases for more than 6 mo, anti-HCV antibodies (Elisa III) and positive PCR HCV-RNA. The viral load at admission and after 12 wk of treatment (EVR) was determined by the classical polymerase chain reaction (Roche) with a detection limit of 600 UI/mL. The viral load 24 wk after the end of treatment (SVR) was determined by real-time PCR (Abbott) with a detection limit of 23 UI/mL. None of the patients presented with clinical, biological, endoscopic or ultrasound signs of liver cirrhosis. We did not perform liver biopsy because of the increased risk of bleeding in haemodialysis patients.

All patients were treated with pegylated-interferon alpha 2a (180 µg/wk) for 48 wk. We evaluated the biochemical response every month and the virological response after 12 wk of treatment (early virological response-EVR) and 24 wk after the end of treatment.

We monitored the side effects during the treatment. At the end of the treatment we evaluated the biochemical response of our patients (number of patients with normal transaminases) and the sustained virological response (SVR) 24 wk after the end of the treatment (72 wk from the beginning of the treatment) by determining the virological load.

**RESULTS**

The 10 patients studied are listed in Table 1. At the beginning of the study the virological load was low in 2 patients (< 10 kIU/mL), moderate in 5 patients (10-500 kIU/mL), and high in 3 patients (> 500 kIU/mL). Two patients were excluded from the study. One patient was excluded because of lack of compliance and 1 patient discontinued the treatment due to complications after surgery (sepsis).

We determined the biochemical and virological response (PCR RNA HCV) in the 8 patients who continued the treatment after 12 wk of therapy. Of these patients, 7 (87.5%) had biochemical response (normal transaminases) as well as virological response (viral load < 0.6 kIU/mL), 1 (12.5%) had biochemical response (normal transaminases) but persistent viremia. We continued the treatment with pegylated-interferon alpha 2a for 48 wk. During this period one patient died of cerebral haemorrhage caused by arterial hypertension after 16 wk of therapy (the patient having normal prothrombin time and only mild thrombocytopenia-104 000 platelets/mL) and one patient was excluded from the study due to lack of compliance after 28 wk of therapy.

The total number of patients who finished the 48-wk treatment was 6 (60%). All of them had biochemical response at the end of treatment (normal transaminases). Three out of 6 patients (50%) had sustained virological response (SVR) 24 wk after the end of the treatment. The intention-to-treat analysis showed that 3 out of 10 patients (30%) had sustained virological response 24 wk after the end of the treatment.

All patients had minor flu-like symptoms, 4 had mild thrombocytopenia (Tr < 150 000/mm$^3$) and 2 had moderate thrombocytopenia (Tr < 100 000/mm$^3$), 4 had transitory mild leucopenia (L < 4000/mm$^3$). In the 6th mo of therapy one of the patients developed sepsis secondary to central venous catheter infection. During this period the patient had elevated transaminases. Unfortunately, this patient abandoned the treatment one month later.

We modified the dose of pegylated-interferon in 2 patients. In one we reduced it to 135 µg/wk for 1 mo (because of the thrombocytopenia and haemorrhagic complications-metroragia, epistaxis, prolonged bleeding of the fistula), then 180 µg/wk was administered again. In the second patient the dose reduction to 135 µg/wk was initiated in the 4th mo of therapy until the end of 48-wk treatment.

We did not stop the treatment in any patient due to severe side effects of pegylated-interferon.
This page contains a table and a discussion section.

**DISCUSSION**

Many clinical trials have focused on the treatment of chronic hepatitis C patients on chronic haemodialysis with standard interferon, because ribavirin is not recommended. Some studies have used ribavirin at low doses (1.70-300 mg/d) together with standard interferon. The results are encouraging but a careful monitoring of anaemia is mandatory. When anaemia occurs it is corrected with high doses of erythropoetin. On the other hand, post-transplant treatment of chronic C hepatitis with interferon is not recommended because it can induce graft rejection (15.4%-63.6% of cases). Also, post-transplant monotherapy with ribavirin or amantadine has been proven inefficient.

Fabrizi et al. have found a mean SVR of 37% and a mean dropout rate of 17% in chronic hepatitis C patients on dialysis after interferon monotherapy. Our experience in treatment of these patients with standard interferon showed that sustained biochemical response is 46.1% and sustained virological response (HCV-RNA) is 38.4% respectively 6 mo after interferon treatment.

The promising results of monotherapy with standard interferon in chronic haemodialysis patients with chronic hepatitis C have shown that viral clearance occurs in 27%-64% of patients after 12 mo of treatment with standard interferon.

In patients on chronic haemodialysis, the combined treatment with interferon and ribavirin is difficult to manage because haemolysis is induced by ribavirin. There are studies in which ribavirin is administered at low doses (170-300 mg/d), the results are remarkable but anaemia should be carefully monitored.

The second therapeutic option for patients on chronic haemodialysis with chronic C hepatitis is to use pegylated interferon. In most of the studies performed in patients with chronic C hepatitis and normal renal function, the response rate doubled when the patients switched from standard interferon to pegylated-interferon. Some 3rd phase studies have been performed in Greece, Mexico, Great Britain and USA to evaluate the sustained virological response after treatment with pegylated interferon alpha 2a in patients on chronic haemodialysis.

Martin et al. demonstrated that the absorption, distribution and total clearance of pegylated-interferon alpha 2a (40 ku) are not very different from those in patients with normal renal function, and that the tolerability of pegylated-interferon alpha 2a and the adverse effects in patients on chronic haemodialysis are similar with those in patients without renal impairment. In our group the side effects were quite the same with those in “normal” patients with chronic hepatitis C treated with pegylated-interferon.

We reduced the dose of pegylated-interferon to 135 µg/wk in 2 cases (in one patient only for one month and in another until the end point of treatment). Various authors have recommended a dose of 180 or 135 µg/wk of pegylated-interferon alpha 2a in patients on chronic haemodialysis. We prefer to start with 180 µg/wk in order to reduce the dosage if severe side effects occur. We reduced the dosage in 2 patients due to thrombocytopenia and bleeding.

Data on the patients on haemodialysis treated with pegylated-interferon alpha 2b are rather discouraging. A study by Russo et al. on the HCV-infected patients on haemodialysis treated with pegylated-interferon alpha 2b showed that a poor tolerance is associated with substantial side effects. Also, a case report by Potthoff et al. showed that IFN-alpha 2b three times a week after haemodialysis seems to be better tolerated than pegylated-interferon-alpha 2b once a week. A randomized study performed by Mahmoud et al. in pretransplant haemodialysis patients with chronic hepatitis C, treated with standard interferon alpha 2b, showed that IFN-treated patients have significantly better post-transplant hepatic functions and significantly lower rates of chronic allograft nephropathy. Further studies are needed to find out which type of interferon is better tolerated and has better results for the treatment of haemodialyzed patients with chronic hepatitis C.

Since there are more and more encouraging results of treatment with interferon in patients on chronic haemodialysis with chronic hepatitis C, it is likely that very soon all these patients can benefit from antiviral therapy (standard interferon alone or in combination with ribavirin, or pegylated-interferon).

After 12 wk of treatment with Peg-Interferon alpha 2a (40 ku) in patients on chronic haemodialysis with chronic C hepatitis, the early virological response (EVR) (HCV-RNA absent by PCR) was obtained in 87.5% (7/8) of the cases. All the patients that finished the 48 wk of treatment had normal transaminases (biochemical response) (6/6).

We had to reduce the dose of Peg-Interferon in only 2 cases. Even if side effects occurred in most of the patients
REFERENCES

1. Lombardi M, Cerrai T, Geatti S, Negroni S, Pertusini L, Pegoraro M, Di Lullo G. Results of a national epidemiological investigation on HCV infection among dialysis patients. (Survey by the Italian Branch of EDTNA/ERCA). J Nephrol 1999; 12: 322-327

2. Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000; 61: 44-51

3. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universités Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53: 1022-1025

4. Schneeberger PM, Keur I, van der Vliet W, van Hoek K, Boswijk H, van Loon AM, van Dijk WC, Kauffmann RH, Quint W, van Doorn LJ. Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods. J Clin Microbiol 1998; 36: 1711-1715

5. Tokars JI, Frank M, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States. 2000. Semin Dial 2002; 15: 162-171

6. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003, 18: 1071-1081

7. Saxena AK, Panhotra BR, Naguib M, Aboras MN, Sundaram DS, Venkateshappa CK, Khan WU. Prevalence of hepatitis C antibodies among hemodialysis patients in Al-hasa region of saudi arabia. Saudi J Kidney Dis Transpl 2001; 12: 562-565

8. Jaiswal SK, Chitnis DS, Salgia P, Sepaha A, Pandit CS. Prevalence of hepatitis viruses among chronic renal failure patients on haemodialysis in central India. Dial Transplant 2002; 31: 234-240

9. Yilmaz ME, Kara IH, Sari Y, Zinzen S, Usul Y, Isikoglu B. Seroprevalence and risk factors of HCV in dialysis patients in a university hemodialysis center of southeast Anatolia, Turkey. Dial Transplant 2001; 30: 748-755

10. Fabrizi F, Poodnad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10

11. Okuda K, Hayashi H, Kobayashi S, Irie Y. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients. J Hepatol 1995; 23: 28-31

12. dos Santos JP, Loureiro A, Cendoroglo Neto M, Pereira BJ. Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units. Nephrol Dial Transplant 1996; 11: 2017-2022

13. Zampieron A, Jayasekera H, Elseviers M, Lindley E, De Vos JY, Visser R, Harrington M. European study on epidemiology and the management of HCV in the haemodialysis population.-Part 1: centre policy. EDTNA ERCA J 2004; 100: 84-90

14. Furusyo N, Kubo N, Nakashima H, Kashiwagi K, Etoh Y, Hayashi J. Confirmation of nosocomial hepatitis C virus infection in a hemodialysis unit. Infect Control Hosp Epidemiol 2004; 25: 584-590

15. Izopet J, Sandres-Saune K, Kamon N, Salama G, Dubois M, Pasquier C, Rostaing L. Incidence of HCV infection in French hemodialysis units: a prospective study. J Med Virol 2005; 77: 70-76

16. Martin P, Carter D, Fabrizi F, Dixit V, Conrad AJ, Artinian L, Peacock V, Han S, Wilkinson A, Lassman CR, Danovitch G. Histopathological features of hepatitis C in renal transplant candidates [see comment]. Transplantation 2000; 69: 1479-1484

17. Magnone M, Holley JL, Shapiro R, Scandelybury V, McCauley J, Jordan M, Vivas C, Starzl T, Johnson JP. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 1068-1070

18. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431

19. Kamar N, Sandres-Saune K, Selves J, Ribes D, Cointault O, Durand D, Izopet J, Rostaing L. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184-192

20. Kamar N, Toupane O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092-2098

21. Tan AC, Brouwer JT, Glue P, van Leusen R, Kauffmann RH, Schalm SW, de Vries RA, Vroom B. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001; 16: 193-195

22. Sporea I, Golea O, Ursu C, Totolici C, Popescu A, Sirli R et al. Effect of alpha 2b Interferon Treatment in Haemodialysis Patients with Chronic C hepatitis. Rom J Gastroenterol 2001; 4: 285-288

23. Bruchfeld A, Stähle L, Andersson J, Schwarz R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection—a pilot study. J Viral Hepat 2001; 8: 287-292

24. Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights. Nephrol Dial Transplant 2000; 15 Suppl 8: 74-76

25. Rostaing L, Izopet J, Mousson F, Alric L, Verdier D, That HT, Duffaut M, Durand D, Puel J, Suc JM. HCV RNA clearance after treatment with interferon-alpha in chronic hemodialysis patients with or without coinfection by HGV/HGBV-C. Nephrologie 1997; 18: 281-286

26. Izopet J, Rostaing L, Mousson F, Alric L, Dubois M, That HT, Payen JL, Duffaut M, Durand D, Suc JM, Puel J. [High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy] J Infect Dis 1997; 166: 1614-1617

27. Huraib S, Iqbal A, Tanimu D, Abdullah A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol 2001; 21: 435-440

28. Martin P, Mitra S, Farrington K, Martin NE, Modi WN. Pegylated (40ku) Interferon alpha 2a (Pegasys) is unaffected by renal impairment (Abstract). Hepatology 2008; 32: 842

29. Russo MW, Ghalib R, Sigal S, Yoshi V. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006; 21: 437-443

30. Pothisonse A, Wiegand J, Lüth JB, Wedemeyer H, Manns MP, Tillmann HL. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a haemodialysis patient with chronic hepatitis C? Clin Nephrol 2005; 63: 232-235

31. Mahmoud IM, Sobb MA, El-Halashi AF, Sally ST, El-Baz M, El-Sawy E, Ghoneim MA. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephrol Clin Pract 2005; 100: c133-c139

S-Editor Wang J L-Editor Wang XL E-Editor Bi L